Duratia (Dapoxetine Hydrochloride) is a prescription medication specifically formulated for the treatment of premature ejaculation (PE) in adult men. As a selective serotonin reuptake inhibitor (SSRI) with a rapid onset and short half-life, it represents a targeted therapeutic approach designed for on-demand use. Clinical trials have demonstrated its efficacy in significantly increasing intravaginal ejaculatory latency time (IELT) and improving patient-reported outcomes related to control over ejaculation and sexual satisfaction. This medication should be used under strict medical supervision as part of a comprehensive treatment plan that may include psychological counseling and behavioral techniques.

Features

• Active ingredient: Dapoxetine Hydrochloride
• Available in 30 mg and 60 mg film-coated tablets
• Rapid absorption with peak plasma concentration achieved within 1-2 hours
• Short elimination half-life of approximately 1.5-2 hours
• Specifically developed for on-demand use rather than daily dosing
• Manufactured under GMP-certified conditions

Benefits

• Significantly prolongs time to ejaculation, providing greater sexual control
• Improves sexual satisfaction for both partners through enhanced ejaculatory latency
• On-demand dosing allows for spontaneity without requiring daily medication commitment
• Rapid onset of action enables administration 1-3 hours before anticipated sexual activity
• Short half-life minimizes residual drug effects between doses
• Demonstrated improvement in patient-reported outcomes and quality of life measures

Common use

Duratia is indicated for the treatment of premature ejaculation in adult men aged 18-64 years. Premature ejaculation is defined as persistent or recurrent ejaculation with minimal sexual stimulation before, on, or shortly after penetration and before the person wishes it, which causes marked distress or interpersonal difficulty. The medication is intended for men who have established, stable sexual relationships and who meet the diagnostic criteria for lifelong or acquired premature ejaculation. Clinical studies have shown effectiveness across various patient populations, though individual response may vary.

Dosage and direction

The recommended starting dose is 30 mg taken orally 1-3 hours before anticipated sexual activity. Based on efficacy and tolerability, the dose may be increased to 60 mg. The maximum recommended dosing frequency is once every 24 hours. Tablets should be swallowed whole with at least one full glass of water, with or without food. Patients should avoid consuming alcohol while taking Duratia, as alcohol may increase the risk of adverse events such as dizziness, syncope, or orthostatic hypotension. Dose adjustment may be necessary for patients with renal or hepatic impairment.

Precautions

Patients should be cautioned about the potential for orthostatic hypotension, especially during the first few hours after taking Duratia. Those with underlying cardiovascular conditions should use Duratia with particular caution. Patients should be advised to avoid activities requiring alertness, such as driving or operating machinery, until they know how the medication affects them. Those with a history of mania or hypomania should be monitored closely, as SSRIs may precipitate manic episodes. Regular follow-up with the prescribing physician is recommended to assess treatment response and monitor for adverse effects.

Contraindications

Duratia is contraindicated in patients with known hypersensitivity to dapoxetine or any excipients in the formulation. It should not be used in patients with significant cardiac disease, including heart failure, conduction abnormalities, or clinically significant ischemic heart disease. Concomitant use with monoamine oxidase inhibitors (MAOIs), thioridazine, or other SSRIs is contraindicated. Patients with moderate to severe hepatic impairment should not use Duratia. The medication is not recommended for use in women or patients under 18 years of age.

Possible side effects

The most commonly reported adverse reactions include nausea (11.0%), dizziness (5.8%), headache (5.6%), diarrhea (3.4%), insomnia (2.7%), and fatigue (2.1%). These effects are generally mild to moderate in severity and often diminish with continued use. Less common side effects may include orthostatic hypotension, syncope, blurred vision, tinnitus, and anxiety. Serious but rare adverse events include serotonin syndrome, especially when used with other serotonergic drugs, and priapism. Patients should seek immediate medical attention if they experience symptoms such as chest pain, shortness of breath, or prolonged erection.

Drug interaction

Duratia undergoes extensive hepatic metabolism primarily through multiple CYP enzymes, including CYP3A4, CYP2D6, and CYP2C19. Concomitant use with strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin) is contraindicated. Moderate CYP3A4 inhibitors may require dose reduction. Concurrent administration with other serotonergic drugs (tramadol, lithium, triptans) increases the risk of serotonin syndrome. Duratia may potentiate the effects of alcohol and other CNS depressants. Caution is advised when using with alpha-adrenergic blockers due to potential additive effects on blood pressure.

Missed dose

As Duratia is intended for on-demand use rather than continuous dosing, the concept of a “missed dose” does not apply in the conventional sense. Patients should take the medication only when needed, with at least 24 hours between doses. If a dose is taken and sexual activity does not occur or is significantly delayed beyond the medication’s effective window, no additional dose should be taken within the same 24-hour period.

Overdose

Symptoms of overdose may include serotonin syndrome manifestations (agitation, confusion, diaphoresis, tachycardia, hyperthermia), syncope, dizziness, nausea, and vomiting. There is no specific antidote for dapoxetine overdose. Treatment should consist of supportive measures, including monitoring of vital signs and ECG. Gastric lavage may be considered if performed soon after ingestion. Activated charcoal may be administered if the patient presents within one hour of ingestion. Patients should be monitored for at least 24 hours due to the drug’s pharmacokinetic profile.

Storage

Store at room temperature between 15-30°C (59-86°F) in the original container. Protect from light and moisture. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging. Properly dispose of any unused medication through medication take-back programs or according to local regulations.

Disclaimer

This information is provided for educational purposes only and does not constitute medical advice. Duratia is a prescription medication that should only be used under the supervision of a qualified healthcare professional. Patients should consult their physician for proper diagnosis and treatment recommendations. Individual results may vary, and not all patients will experience the same benefits or side effects.

Reviews

Clinical studies involving over 6,000 patients demonstrated that Duratia significantly improved IELT compared to placebo. In phase III trials, mean IELT increased from approximately 0.9 minutes at baseline to 3.1 minutes with 30 mg and 3.6 minutes with 60 mg doses. Patient-reported outcomes showed significant improvements in perceived control over ejaculation and satisfaction with sexual intercourse. Real-world evidence from post-marketing surveillance continues to support the efficacy and safety profile established in clinical trials, though long-term data beyond 24 weeks of treatment remain limited.